会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES
    • 用PSORALEN衍生物治疗细胞增殖障碍的方法和系统
    • WO2010123996A1
    • 2010-10-28
    • PCT/US2010/031902
    • 2010-04-21
    • IMMUNOLIGHT, LLCDUKE UNIVERSITYTOONE, EricGOODEN, DavidBOURKE, Frederic, A., Jr.VO-DINH, Tuan
    • TOONE, EricGOODEN, DavidBOURKE, Frederic, A., Jr.VO-DINH, Tuan
    • A61K31/41
    • C07D493/04A61K31/4433A61K31/453A61K31/4709A61K41/0066A61K45/06A61N5/062A61N5/10
    • Psoralen compounds of Formula (I): wherein (N + Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: (iv), wherein R is C 1 -C 30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents; R 1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl; n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.
    • 式(I)的补骨脂素化合物:其中(N +芳基)是选自式(i) - (iii)的含氮芳族杂环的成员:其中Z是式(ⅳ)的基团,其中 R是C1-C30烃基,其可以是直链,支链或环状的并且含有1至15个碳 - 碳双键,其可以彼此共轭或非共轭或可以包括芳环,并且可以含有一个或多个取代基 ; R 1是氢,芳基,杂芳基,烷基,环烷基,杂环基,烯基,炔基,烯 - 芳基,烯 - 杂芳基,烯烃 - 杂环基,烯 - 环烷基,稠合环烷基芳基,稠合环烷基杂芳基,稠合杂环基芳基,稠合杂环杂芳基,亚烷基稠合环烷基芳基 亚烷基稠合的环烷基杂芳基,亚烷基稠合的杂环基芳基,亚烷基稠合的杂环杂芳基; n为1〜8的整数,X为药学上可接受的抗衡离子; 及其在治疗受试者的细胞增殖障碍的方法中的用途,含有补骨脂素衍生物的药物组合物,用于进行该方法的试剂盒以及使用该方法在受试者中引起自身疫苗效应的方法。
    • 7. 发明申请
    • ADVANCED METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS
    • 用于治疗细胞增殖障碍的先进方法和系统
    • WO2010009106A1
    • 2010-01-21
    • PCT/US2009/050514
    • 2009-07-14
    • BOURKE, Frederic A., Jr.VO DINH, Tuan
    • BOURKE, Frederic A., Jr.VO DINH, Tuan
    • A61K39/00A61K39/38
    • A61N5/062A61K31/4427A61K31/7052A61K31/7056A61K41/008A61K47/55A61K47/551
    • The present invention relates to methods for treating cell proliferation disorders comprising (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated, (2) admimsteπng at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder, and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of vaπous cell proliferation disorders, and the PEPST and EPEP agents and probes
    • 本发明涉及治疗细胞增殖紊乱的方法,其包括(1)向受试者施用至少一种能够同时进行两个光子吸收事件激活并在被激活时实现预定细胞变化的可活化药剂,(2) 将至少一种等离子体激元活性剂施用于受试者,和(3)将来自起始能量源的引发能量施用于受试者,其中所述等离子体激活剂增强或改变施加的引发能量,使得增强或修饰的引发 能量通过原位同步双光子吸收事件激活可激活的药剂,从而导致发生预定的细胞变化,其中所述预定的细胞变化处理细胞增殖相关病症,以及使用等离子体激元增强光谱疗法(PEPST)和离开 - 增效光疗法(EPEP)治疗血管 我们的细胞增殖障碍,以及PEPST和EPEP试剂和探针